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Summary
Background and objectives: To assess the potential neurotoxic effects at the ultrastructural level 
of magnesium sulfate administered intrathecally as a single or multi-dose.
Methods: Our study was conducted with 24 Sprague-Dawley rats that weighed 250-300 g. After a 
4-hour fast, the rats were given 10 mg.kg-1 xylazine chloride intraperitoneal and then randomly 
allocated into three groups. Group I (n = 8) received 0.9% normal saline, Group II (n = 8) was 
given one intrathecal injection of 0.02 mL of 15% magnesium sulphate, and Group III (n = 8) was 
given 0.02 mL of 15% magnesium sulphate once a day for seven days. The injections were given 
within 0.40x50 mm from the lumbar area. After seven days, the animals were sacriﬁ ced under 
anesthesia with an aortic injection of 10% formaldehyde and their tissues were ﬁ xed. The medulla 
spinalis was then examined and histopathologically evaluated under an electron microscope. The 
Kruskal-Wallis test was used for statistical evaluation. A value of p < .05 was considered to be 
statistically signiﬁ cant. 
Results: Signiﬁ cant neurodegeneration was detected in rats given single or repeated magnesium 
sulphate injections compared to the control group. The histopathological evaluation score of 
this group was also high. 
Conclusions: Based on electron microscopic examination, we found that intrathecal magnesium 
sulphate administration induced neurodegeneration.
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Introduction
The discovery of opioid receptors within the spinal cord has 
made drug administration through intrathecal or epidural 
methods universally used for the treatment of acute or chronic 
pain 1. Magnesium sulphate, which has been used in preec-
lampsia and eclampsia as an anticonvulsant for many years, 
has also been used to treat myocardial infarction, some arrhyt-
mias, asthma, pheochromocytoma, and tetanus. In addition, 
magnesium sulphate, which is regarded as a natural calcium 
channel blocker, is a non-competitive antagonist for N-Methyl-
D-Aspartate receptors 2.  Previous studies have proposed that 
magnesium sulphate has a post-operative analgesic effect 
when used intravenously 3. In addition, magnesium sulphate 
has been previously used in humans and animals intrathecally 
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mitochondrial degeneration with disordered structures in 
the granullose endoplasmic reticulum (GER), defect in core 
content, or extracellular edema, 2. A value of 0.5 was also 
used between ﬁ ndings of 0 and 1, as well as 1 and 2. 
Statistical Evaluation
The Kruskal-Wallis test was used to determine signiﬁ cance 
differences between two groups. When an intergroup differ-
ence was detected, the Kruskal-Wallis multiple comparison 
test was applied, in order to determine the group responsible 
for the difference. All values of p < .05 were considered 
statistically signiﬁ cant. 
Results
The daily mobility of rats in Group I and III and the mobility 
of rats in all of the groups during observation at the end of 
the study were normal. None of the animals were excluded 
from the study for any reason. There was no statistical dif-
ference between the rats in all three groups in terms of 
weight prior to the study (Table 1; p > 0.05). The median 
value obtained from histopathologic examinations was 0 
(0-0.5) in the control group, 1 (1-1) in Group II, and 2 (1.5-2) 
in rats from Group III. 
In addition there was a statistically signiﬁ cant differ-
ence in toxicity scores between all three groups (Figure 1A; 
p < 0.001). Toxicity was signiﬁ cantly greater in rats given 
a single dose of magnesium sulphate compared to control 
rate (Figure 1B; p = 0.002). In addition, rats given repeated 
doses of magnesium sulphate had higher toxicities than the 
control (Figure 1C; p = 0.002). Toxicities were also higher if 
rats were given repeated doses of magnesium sulphate com-
pared to rats given a single dose (Group II vs. II, respectively; 
Figure 1D; p = 0.008). 
In electron microscopic examination of the medulla spina-
lis, multipolar neurons with normal structures were observed 
in the control rats, and the cell nucleus was cycloid, centrally 
located, and euchromatic. The nucleolus was also conspicu-
ous, and the cell cytoplasm contained endoplasmic reticu-
lum cysternas that were nubile. The electron intensity was 
dependent on the intensity of ribosome. Mitochondria were 
found to have normal structures and crista (Figure 2). 
In Group II, the electron intensity was dependent on the 
intensity of the ribosomes. The cell nucleus and nucleolus had 
normal structures, and granule and endoplasmic reticulum 
cysternas in the cytoplasm were nubile. These ﬁ ndings were 
similar to the control group. However, when the mitochon-
dria were analyzed, widespread degeneration was observed, 
and distention and crystallization of the mitochondria were 
wide-spread (Figure 3).  
In Group III, very distinct degenerative changes were 
observed. Chromatin loss was evident in the nucleus which 
was not observed. A decrease in the cytoplasmic density 
was observed, and conspicuous dilatation was detected in 
endoplasmic reticulum cysternas. Crystalization in different 
forms was seen in the mitochondria, and very signiﬁ cant 
degenerative changes were observed in the neurons. The 
cells observed from Group III also have a unique increase in 
lysosomes (Figure 4). Based on these observations, ultrastruc-
tural neuro-degeneration was concluded in this group.     
for its analgesic and neuroprotective effects 4,5. However, it is 
known that permanent neurologic sequels may arise following 
spinal or epidural administration of the drug 6.
The aim of this study was to investigate the potential 
neurotoxic effects of the intrathecal use of magnesium 
sulphate at the ultrastructural level.
Materials and methods
This study was conducted in the animal laboratory of the 
Gülhane Military Medical Faculty with permission from the 
Ankara University Veterinary Faculty Ethics Committee. 
Twenty-four Sprague-Dawley rats weighing 250-300 g were 
included in the study. Rats were fed 20% proteinaceous chow 
and provided water ad libitum in accordance with the prin-
ciples of utilization and supervision of laboratory animals. 
Prior to the experiment, the animals were maintained under 
a 12h:12h night/day schedule under optimum conditions of 
20-22°C and 55% humidity. During the experiments, the same 
conditions were maintained and rats were separately housed 
in polycarbonate cages.  
After a 4-hour fast, the rats were given an intraperito-
neal injection of 100 mg.kg-1 ketamine hydrochloride and 
10 mg.kg-1 xylazine chloride. After the rats were anesthe-
tized, the surgical area was shaven, cleaned, and then sub-
jected to intrathecal implementation within a 0.40x50 mm 
area of the lumbar L5-6 range. After ceretrospinal ﬂ uid (CSF) 
was observed, a total of 0.02 mL of study solution was in-
jected through a Hamilton injector (28 gauge, sharp pointed, 
SGE, Australia). Following the intrathecal implementation, 
rats were observed for clinical toxicity until they began to 
walk on their own and consume nourishment.     
The rats were randomly allocated into three groups for 
intrathecal injections. Group I (n = 8) was given 0.02 mL 
0.9% normal saline, Group II (n = 8) was given 0.02 mL 15% 
magnesium sulphate, and Group III (n = 8) was given 0.02 mL 
magnesium sulphate once a day for seven days. Each injection 
was given within a region of 0.40x50 mm from the lumbar 
area. Following immediate observation of mobility for signs 
of clinical toxicity, all of the rats were sacriﬁ ced under 
anesthesia on the 8th day with an aortic injection of 10% 
formaldehyde; then, their medulla spinalis was analyzed.  
Tissue samples (1 mm3) from the lumbar area were 
incubated for two hours in 2% glutaraldehyde (pH 7.4) in 
phosphate-buffered saline (PBS). At the end of the incubation 
the tissues were washed three times with PBS and then post-
ﬁ xed in 1% osmium tetroxide for one hour. The tissue samples 
were then dehydrated in a series of alcohols. Finally, the 
tissues were treated with propylene oxide and then mounted 
as tissue blocks using the Araldite CY212 kit 5x100 g Epoxy 
resin (Araldite CY212). Half gracilis incisions were made in 
the blocks, which were polymerized at 56°C and stained with 
toluidine blue. Gracilis muscle was then isolated from areas 
marked after assessment by light microscopy, stained with 
uranyl acetate-lead citrate, and then assessed with a Carl 
Zeiss EM 900 transmission electron microscope (TEM).  
Histopathological Changes  
Histopathological changes were scored as follows: normal ul-
trastructure, 0; degenerative changes in mitochondria where 
the core content and other organelles were normal, 1; and 
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Figure 1  A) Toxicity Scores of Group I, Group II, and Group III. B) Comparison of Toxicity Scores of Group I and Group II. C) 
Comparison of Toxicity Scores of Group I and Group III. D) Toxicity Scores of Group II and Group III.
Table 1  The Body Weights of Rats Before and After the Study.
No. Group
Body Weight
First Day (g)
Body Weight
Last Day (g)
p
I Control 268 ± 17 269 ± 14 > 0.05
II Single Dose 271 ± 16 273 ± 15 > 0.05
III Repeated Dose 265 ± 17 266 ± 15 > 0.05
Discussion
The lack of severe side effects during intravenous usage 
and the increased application for analgesia indications 
has made the use of intravenous magnesium sulphate a 
common subject of scientiﬁ c studies. More recently, the 
use of magnesium sulphate has been explored in general 
anesthesia as well 7,8. Magnesium sulphate is known to be 
an N-methyl-D-aspartate (NDMA) receptor antagonist and 
can block ion channels associated with it. NMDA receptor 
antagonists may block the central sensitivity associated 
with peripheral nociceptive stimulation. Studies show that 
NMDA receptor antagonists have little effect on direct C pain 
ﬁ brils, but their effect may increase substantially during 
repeated stimulation 9. A study by Mitani et al. demonstrated 
that functional changes in NMDA receptor channels may 
play speciﬁ c roles in neuronal damage 10. Previous studies 
show that magnesium can reduce acetylcholine release 11. 
Since magnesium sulphate depresses cholinergic tonus, this 
mechanism may play a role in motor block formation 12. On 
the other hand, Cheng et al. suggest that glutamate can 
increase the intracellular magnesium concentration, which 
may cause neurotoxicity. 
In the Dror 4 case study, we found that when 10% magne-
sium sulphate was given epidural by mistake, irritation in the 
form of burning was reported, but a motor or sensory block 
did not occur 4. In another case, an intrathecal injection of 
2 mL of 50% magnesium sulphate given by mistake caused 
motor paralysis for ﬁ ve hours and a severe headache, albeit 
without any sensation loss 5.
In Chanimov 13, rats were given spinal anesthesia through 
intrathecal serial injections of magnesium sulphate and there 
was more vacuolization in the ganglion cells of gray matter in 
the group given 0.02 mL of 12.6% magnesium sulphate com-
pared to groups  given 6.3% of sulphate, 2% lidocaine, 0.9% 
SF, or with only an intrathecal catheter attached. In another 
study, rats given 6.3% magnesium sulphate by intrathecal 
catheter developed spinal anesthesia and general sedation 
over a one week period compared to rats administered 2% 
lidocaine 14. In addition, the rats given magnesium sulphate 
developed clinical neurotoxicity and neurologic deﬁ cit. 
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Nerve lesions are formed after ischemic, traumatic, or 
toxic effects. These lesions may involve spinal toxicity axons 
and many components of the neural system that can directly 
affect the tunics, such as vascular damage and scar tissue. 
In addition, some local anesthetics may reduce blood stream 
ﬂ ow and have toxic effects 15,16. Moreover, the neurotoxic 
inﬂ uence may not only affect cytoplasmic formation, but 
may also directly affect the nucleus 17.
Several previous neurotoxicity studies 18-20 have explored 
single and multi-dose injections through an intrathecal 
or epidural catheter. Since the consent is that the use of 
intrathecal catheters may also cause histopathological 
changes, we subjected a study group to a repeated dose 
regimen as well as a single dose regimen, given that both 
are used in routine clinical practice. In recent studies, 
epidural granulation formation as well as medulla spinalis 
and massive ﬁ brinolysis in the spinal roots were observed 
in animal models subjected to intrathecal cannulation and 
drug administration at epidural and subarachnoid intervals. 
Parenchymal infarction and abscess were also noted dur-
ing the infusion of a synthetic drugs. However, since some 
of these changes were also present in the control group 
animals, which were only infused with normal saline, it is 
rather difﬁ cult to distinguish the drug-induced changes from 
other changes due to chronic catheter use alone. In addi-
tion, some evidence has indicated that the catheter itself 
can block the drainage of CSF and causes changes related 
to this condition 21. 
It is unclear whether morphologic studies used to deter-
mine the neurotoxic effects of a compound through intrathe-
cal administration sufﬁ ce, because the compound-mediated 
toxicities may have more of an effect on cellular function than 
cell structure. The absence of morphological changes is not 
sufﬁ cient for determining whether a compound has a potential 
neurotoxic effect. Therefore, morphological and functional 
studies must be conducted concomitantly during toxicological 
analysis of a compound poised for human use 22.     
In this study, signiﬁ cant neurodegeneration was observed 
after magnesium sulphate administration, particularly during 
repeated dosing. This degeneration may be a result of an 
extreme increase in cellular activity and simultaneous deﬁ cit 
in energy metabolism. This degeneration not only affects 
the cytoplasmic structure, but may also affect the nucleus. 
Therefore, intracellular magnesium accumulation may also 
be responsible for neurodegeneration.   
Direct neurotoxic effects are thought to be associated 
with a concentration of previously administered agents 23. 
However, in some cases, compounds that have been shown to 
have potential neurotoxicity in animal models end up being 
clinically safe in humans at certain doses or concentrations 24. 
In this study, we suggest that the intrathecal administration 
of magnesium sulphate at concentrations of 15% or higher 
may cause unforeseen risks for the patient.  
Figure 3  Neuron Electron Microscopic Examination in the 
Group which was Subjected to Single Dose of Magnesium 
Sulphate. 
N: Nucleus; GER: Granular Endoplasmic Reticulum; *electron 
intensive cytoplasm. All in normal structure. Crystolysis is observed 
in mitochondria (uranyl-acetate-lead citrate 440x2.10 μm).
Figure 4  Loss of Chromatin, GER Dilatation, a Decrease 
in Cytoplasmic Intensity (*) and Crystolysis is conspicuous 
in the nucleus of the neurons of the group, which was 
subjected to repeated magnesium sulphate implementation 
(uranyl acetate-lead citrate 440x2.10 μm).
Figure 2  Electron Microscopy of Neurons. 
N: Nucleus; GER: Granular Endoplasmic Reticulum; M: Mitochondria; 
*electron intensive cytoplasm. Examined in normal view (uranyl 
acetate-lead citrate 440x2.10 μm). 
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In this study, no disorders in rat motility were observed 
after the intrathecal administration of magnesium sulphate. 
Nevertheless, based on the microscopic examination of each 
group, we hypothesize that the signiﬁ cant neurodegeneration 
is observed is still important, particularly at the repeated 
dosing of 15% magnesium sulphate. Moreover, it is unknown 
what effect this dosing has on the blood brain barrier, spinal 
blood stream, and nerve conductions, since the neurophysi-
ological studies could not be implemented due to technical 
difﬁ culties. In cases where magnesium sulphate administra-
tion may be clinically useful, such as for Windup pains that 
do not respond to opioids 25, long-term use may be needed. 
We have not found any neurophysiologic study to date related 
to the intrathecal usage of magnesium sulphate on experi-
ment animals.  
In conclusion, this study suggests that the intrathecal 
administration of magnesium sulphate at concentrations of 
15% or higher may cause unforeseen risks for the patient. 
Neurodegeneration was observed by electron microscopy in 
animals given magnesium sulphate at this concentration, es-
pecially after repeated administration, and may be the result 
of an extreme increase in cellular activity and subsequent 
deﬁ cit in energy metabolism. The neurophysiological studies 
related to the usage of magnesium sulphate to date have 
been insufﬁ cient for evaluating clinical safety and, therefore, 
additional studies are needed for full characterization.   
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